{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:59Z","timestamp":1781650679932,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of immune checkpoint inhibitors may cause neurological immune-related adverse events in patients. Here, we report a case of autonomic nervous system involvement in nivolumab-induced autoimmune encephalitis with dysautonomia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 78-year-old man presented with a 4-month history of orthostatic hypotension, dysgeusia, and dysosmia following a 2-month course of nivolumab prescribed for malignant mesothelioma. Serum was positive for anti-neuronal nuclear antibody type 1. Diagnostic work-up, including imaging, neurological, and biochemical tests, suggested the diagnosis of nivolumab-induced autoimmune encephalitis with pronounced autonomic nervous system involvement. On day 10 of hospitalization, the patient received high-dose intravenous methylprednisolone followed by oral prednisone. The patient was discharged on day 29 with continued administration of corticosteroids and midodrine. At the 1-month outpatient follow-up, the patient remained stable and reported independent ambulation without marked orthostatic symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We discuss a possible mechanism of dysautonomia in this case and draw attention to newly emerging autonomic symptoms and olfactory impairments during therapy with immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04880-y","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:18:03Z","timestamp":1776813483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dysautonomia and dysosmia associated with anti-Hu antibodies induced by immune checkpoint inhibitors: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Masataka","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Igari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6766-5145","authenticated-orcid":false,"given":"Motoki","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"4880_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017;73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001.","journal-title":"Eur J Cancer"},{"key":"4880_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, et al. Neurologic adverse events of immune checkpoint inhibitors: A systematic review. Neurology. 2021;96:754\u201366. https:\/\/doi.org\/10.1212\/WNL.0000000000011795.","journal-title":"Neurology"},{"key":"4880_CR3","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1014. https:\/\/doi.org\/10.1212\/NXI.0000000000001014.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4880_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/practneurol-2013-000520","volume":"14","author":"HA Archer","year":"2014","unstructured":"Archer HA, Panopoulou A, Bhatt N, Edey AJ, Giffin NJ. Mesothelioma and anti-Ma paraneoplastic syndrome; heterogeneity in immunogenic tumours increases. Pract Neurol. 2014;14:33\u20135. https:\/\/doi.org\/10.1136\/practneurol-2013-000520.","journal-title":"Pract Neurol"},{"key":"4880_CR5","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1007\/s00415-023-11667-5","volume":"270","author":"T Tezuka","year":"2023","unstructured":"Tezuka T, Okuzumi S, Nakashima C, Ide T, Imai S, Mitsuboshi S, et al. Dysautonomia associated with immune checkpoint inhibitors. J Neurol. 2023;270:3413\u201323. https:\/\/doi.org\/10.1007\/s00415-023-11667-5.","journal-title":"J Neurol"},{"key":"4880_CR6","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1007\/s00415-022-10959-6","volume":"269","author":"A Morano","year":"2022","unstructured":"Morano A, Cerulli Irelli E, Fanella M, Orlando B, Salamone EM, Tinelli E, et al. Olfactory impairment in autoimmune encephalitis: Another piece of the puzzle. J Neurol. 2022;269:2762\u20138. https:\/\/doi.org\/10.1007\/s00415-022-10959-6.","journal-title":"J Neurol"},{"key":"4880_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus F, Keime-Guibert F, Re\u00f1e R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain. 2001;124:1138\u201348. https:\/\/doi.org\/10.1093\/brain\/124.6.1138.","journal-title":"Brain"},{"key":"4880_CR8","doi-asserted-by":"publisher","first-page":"fcad247","DOI":"10.1093\/braincomms\/fcad247","volume":"5","author":"M Villagr\u00e1n-Garc\u00eda","year":"2023","unstructured":"Villagr\u00e1n-Garc\u00eda M, Farina A, Mu\u00f1iz-Castrillo S, Wucher V, Dhairi M, Timestit N, et al. Revisiting anti-Hu paraneoplastic autoimmunity: Phenotypic characterization and cancer diagnosis. Brain Commun. 2023;5:fcad247. https:\/\/doi.org\/10.1093\/braincomms\/fcad247.","journal-title":"Brain Commun"},{"key":"4880_CR9","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","volume":"97","author":"V Nersesjan","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup LH, Kondziella D. Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: A systematic review. Neurology. 2021;97:e191\u2013202. https:\/\/doi.org\/10.1212\/WNL.0000000000012122.","journal-title":"Neurology"},{"key":"4880_CR10","doi-asserted-by":"publisher","first-page":"e200058","DOI":"10.1212\/NXI.0000000000200058","volume":"10","author":"A Farina","year":"2023","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Ciano-Petersen NL, Vogrig A, Mu\u00f1iz-Castrillo S, Taillandier L, et al. Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200058. https:\/\/doi.org\/10.1212\/NXI.0000000000200058.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04880-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:14Z","timestamp":1781649074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04880-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4880"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04880-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8159562\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report is based on clinical observations without experimental intervention. Written informed consent for participating in the case report and publication was obtained from both the patient and patient\u2019s family in accordance with institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors confirm that written informed consent for publication of the clinical details and accompanying images in this report was obtained from both the patient and patient\u2019s family. Additional consent was obtained for publication of any potentially identifying information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}